Importance of dose selection in novel oral anticoagulants for atrial fibrillation;Importancia de seleccionar la dosis de los nuevos anticoagulantes orales para fibrilaciÓn auricular

Archivos de Cardiologia de Mexico

Volumn 82, Issue 4, 2012, Pages 308-311

  Grip, Laura T ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Intracranial bleeding; Oral anticoagulants; USA; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; CREATININE; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; DRONEDARONE; EDOXABAN; PLACEBO; QUINIDINE; RIVAROXABAN; TBD; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MORTALITY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; THROMBOEMBOLISM;

EID: 84871292062     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acmx.2012.10.001     Document Type: Short Survey

References (12)

1. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-52.
2. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamicsand pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin pharmacokinet. 2009;48:1-22.
3. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-41.
4. Ruff CT, Giugliano RP. New oral antithrombotic strategies. Hot Topics in Cardiology. 2009;4:7-14.
5. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419-26.
6. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925-36.
7. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallelgroup, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
10. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
11. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541-54.
12. Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105:535-44.